---------------------------- 2024 Platform Presentation Winner --------------------------

 

Endometrial Gastric (Gastrointestinal)-Type Mucinous Adenocarcinoma (EGA): A Clinicopathologic & Molecular Analysis of 17 Cases

Harsimar Kaur, Lawrence Hsu Lin, David L. Kolin, Andre Pinto, Carlos Parra-Herran, Koen Van de Vijver, Glenn McCluggage, Marisa Rose Nucci

Background: EGA was introduced as a distinct entity in the latest WHO classification of female genital tumors but is rare with a limited number of cases reported. Herein, we report the clinicopathologic, immunohistochemical and, in a subset, molecular profiles of the largest series of EGA to date.

Design: Cases that met established criteria for EGA (gastric/gastrointestinal differentiation with supportive [at least focal positive for gastric and/or intestinal markers] immunohistochemistry (IHC)) were confirmed from review of available materials. Clinical data was retrieved, and histology, IHC, and available molecular results (n=7) reviewed.

Results: The cohort consisted of 17 patients (median age 67 years; range 42 to 78 years; 13/17 postmenopausal). None had known Peutz Jeghers syndrome (PJS). In all, bulk of the tumor was centered in the corpus (4 polypoid, 3 endophytic, 3 ill defined). Size ranged from 1.5-8.2 (mean 4.8) cm. FIGO stage ranged from IA to IVB (Table 1). 13/17 had >50% myometrial invasion, 12/17 had LVI (9/12 substantial) and 7/17 had lymph node involvement (1 with ITC). All showed gastric/gastrointestinal differentiation: granular/foamy apical cytoplasm with distinct cell borders (9), goblet (4), signet ring (3), Paneth (1) cells. 5 had <5% solid growth (FIGO grade 1 architecture; 8 grade 2 and 4 grade 3). Tumors were positive for MUC6 (7/13), CK20 (8/12), CDX2 (15/16) and Claudin 18 (4/7). 10/17 were p53 mutant (2 with “terminal differentiation”) and 2/14 showed MLH1 and PMS2 loss with MLH1 gene promoter methylation. STK11 was retained in 7/8 and equivocal in 1. HER2 was 3+ positive with ERBB2 amplification (1), 2+ (5) and 0 (1).

Next generation sequencing showed pathogenic variants in TP53 (7/7), KRAS (3/7), BRAF (1/7), and SMAD4 (1/7). Outcome data (13 patients; 2-48 months) showed: 1 patient dead of disease 14 mo after diagnosis; 8 alive with disease including 1 with multi-site metastasis (14 mo) and 1 with lung metastasis (48 mo); and 4 patients alive with no evidence of disease (9-47 mo).

Results Table:
Case # Age Presenting symptom Location of tumor FIGO Stage % myometrial invasion LVSI Relevant POSITIVE IHC results Relevant NEGATIVE IHC results
1 50 Intermenstrual bleeding LUS IA None No PAX8, MUC6, ER (weak), CDX2 CK20, PR, p53 wild-type, MMR (intact)
2 67 Postmenopausal bleeding, pelvic pain Fundus IB More than 50% Yes, substantial CK20, CDX2, loss of MLH1 and PMS2 PAX8, ER, PR, p53 wild-type
3 78 Urinary symptoms Fundus and body IB More than 50% Yes, substantial PAX8, CDX2, p53 mutant MUC6, ER, MMR (intact)
4 87 NA Endometrium IB More than 50% No PAX8, MUC6, Claudin 18, CDX2, ER (focal), PR (focal), p53 mutant (terminal differentiation), HER2 (2+)
5 44 Fibroid LUS IB More than 50% Yes, substantial PAX8, CDX2, ER (rare), p16 (diffuse), p53 mutant PR
6 71 Postmenopausal bleeding Fundus IB More than 50% No PAX8, GATA3, CDX2, HNF1beta ER, PR, CK20, MUC6, p53 wild-type, MMR (intact)
7 66 NA Endometrium and invasion of cervical stroma II More than 50% Yes PAX8, p16 (diffuse), Napsin A, MUC6, CDX2, Claudin 18, mucicarmine, p53 mutant (null-pattern), HER2 (2+) ER, PR, CK20, MMR (intact)
8 64 Bilateral complex masses Endometrium, bilateral ovaries, and fallopian tubes IIIA None No CDX2, CK20, p53 mutant PAX8, ER, PR, MMR (intact)
9 42 NA Endometrium, right adnexa IIIA None No CDX2, MUC6, Subclonal loss of ARID1A, p53 mutant CK20, PTEN (retained)
10 73 Postmenopausal bleeding Fundus and body IIIB More than 50% Yes, focal CK20, CDX2, MUC6, loss of MLH1 and PMS2 PAX8, ER, PR, p53 wild-type
11 71 Postmenopausal bleeding Fundus and body IIIC1 More than 50% Yes, substantial MUC6, Claudin 18, CK20, CDX2, p53 mutant ER, PR, HER2 (0), MMR (intact)
12 69 Postmenopausal bleeding, abdominal pain Body IIIC1 More than 50% Yes, substantial P53 mutant, AMACR, Napsin A ER, PR, MMR (intact)
13 75 Postmenopausal bleeding Endometrium, bilateral ovaries, and right fallopian tubes IIIC1 More than 50% Yes, substantial PAX8, CK20, mucicarmine, CDX2, p53 mutant (overexpressed), HER2 (2+) ER, PR, MUC6, Claudin 18, MMR (intact)
14 62 Postmenopausal bleeding Body IIIC2 More than 50% Yes, substantial PAX8, ER (rare) MUC6, CDX2, p53 wild-type, MMR (intact)
15 75 Postmenopausal bleeding Body (multifocal) IIIC2 More than 50% Yes CDX2, CK20, HER2 (2+) PAX8, ER, PR, MUC6, Claudin 18, p53 wild-type, MMR (intact)
16 67 NA Endometrium, cervical stroma, and right adnexa IIIC2 More than 50% Yes, substantial CK20, CDX2, p16 (diffuse), HER2 (3+), PD-L1 >1 PAX8, ER, PR, MUC6, Claudin18, HPV ISH, p53 wild-type, MMR (intact)
17 48 Pelvic pain LUS, bilateral ovaries and fallopian tubes, peritoneum IVB Less than 50% Yes, substantial PAX8, MUC6, Claudin18, CK20, CDX2, p53 mutant (terminal differentiation), HER2 (2+) ER, PR, MMR (intact)



Conclusions: Like their cervical counterpart, primary EGA have a distinctive morphologic appearance, harbor frequent TP53 mutations and can be associated with adverse outcome despite well differentiated glandular morphology and/or low stage disease. In contrast, they do not appear to be associated with PJS or STK11 alterations, although number of cases studied is small.

 


Chat With ISGYP

close
First Name *
Last Name *
Email *
Customer ID